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describe a “hierarchy of evidence” ranging from case 
 studies and uncontrolled trials to randomized controlled 
trials that support the utility, if not the effi cacy, of various 
forms of psychodynamic psychotherapy for treatment of 
patients with a wide range of DSM-IV axis I and II psy-
chiatric disorders. Although each of these meta-analyses 
attempts, in its own way, to make use only of studies that 
are considered of high enough quality to warrant inclusion 
in a meta-analysis, there is sharp disagreement in the fi eld 
about whether the quality and number of studies included 
is suffi cient to warrant the conclusions drawn.
Ambiguity about the state of psychodynamic empiri-
cal research presents a signifi cant problem for training 
and practice in the mental health fi elds. The objective 
evaluation of the quality of randomized controlled tri-
als of psychodynamic psychotherapy is a cogent place to 
begin the process of correcting this problem. Such trials 
are widely accepted in medicine as the gold standard for 
assessing treatment effi cacy, and there is good conceptual 
The depth and quality of the evidence base for psy-
chodynamic psychotherapy has long been a subject of 
controversy among psychodynamic and nonpsychody-
namic clinicians and researchers. Some have argued that 
the relative absence of randomized controlled trials has 
doomed psychodynamic treatments to obsolescence (1). 
This argument is sometimes used to support the further 
marginalization or even elimination of training in psycho-
dynamic techniques in psychiatry, psychology, and social 
work training programs, to be replaced by “evidence-
based treatments” (2).
Others have argued that a body of empirical evidence 
for psychodynamic treatments exists and is underappre-
ciated in the context of contemporary emphasis on short-
term, manualized, and symptom-focused treatments and 
targeted medications (3–5). Over the past several years, 
meta-analyses have appeared in mainstream research 
outlets that argue for the effi cacy of psychodynamic treat-
ments for specifi c disorders (6–11). Gabbard et al. (12) 
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Objective: The Ad Hoc Subcommittee 
for Evaluation of the Evidence Base for 
Psychodynamic Psychotherapy of the 
APA Committee on Research on Psychi-
atric Treatments developed the Ran-
domized Controlled Trial Psychotherapy 
Quality Rating Scale (RCT-PQRS). The 
authors report results from application 
of the RCT-PQRS to 94 randomized con-
trolled trials of psychodynamic psycho-
therapy published between 1974 and 
May 2010.
Method: Five psychotherapy researchers 
from a range of therapeutic orientations 
rated a single published paper from each 
study.
Results: The RCT-PQRS had good inter-
rater reliability and internal consistency. 
The mean total quality score was 25.1 
(SD=8.8). More recent studies had higher 
total quality scores. Sixty-three of 103 
comparisons between psychodynamic 
psychotherapy and a nondynamic com-
parator were of “adequate” quality. Of 
39 comparisons of a psychodynamic 
treatment and an “active” comparator, 
six showed dynamic treatment to be su-
perior, fi ve showed dynamic treatment to 
be inferior, and 28 showed no difference 
(few of which were powered for equiva-
lence). Of 24 adequate comparisons of 
psychodynamic psychotherapy with an 
“inactive” comparator, 18 found dynamic 
treatment to be superior.
Conclusions: Existing randomized con-
trolled trials of psychodynamic psycho-
therapy are promising but mostly show su-
periority of psychodynamic psychotherapy 
to an inactive comparator. This would be 
suffi cient to make psychodynamic psycho-
therapy an “empirically validated” treat-
ment (per American Psychological Associa-
tion Division 12 standards) only if further 
randomized controlled trials of adequate 
quality and sample size replicated fi ndings 
of existing positive trials for specifi c disor-
ders. We do not yet know what will emerge 
when other psychotherapies are subjected 
to this form of quality-based review.
A Quality-Based Review of Randomized Controlled 
Trials of Psychodynamic Psychotherapy
Reviews and Overviews
Evidence-Based Psychiatric Treatment
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outcome literature. Our hypotheses were 1) that the overall 
quality of randomized controlled trials of psychodynamic 
psychotherapy has improved over time, from a largely 
inadequate implementation in the 1970s and 1980s to 
more rigorous implementation in the 1990s and 2000s; 2) 
that some aspects of psychodynamic psychotherapy trials, 
including characterization of patients, reliable and valid 
measurement of outcome, and manualization of treat-
ment, are now being done quite well; and 3) that some 
aspects of psychodynamic psychotherapy trials, includ-
ing reporting of therapist training and supervision, mea-
surement of treatment adherence, analysis of therapist or 
study site effects, and reporting of concurrent treatments 
and adverse events during treatment, remain lacking.
Method
Sample
We conducted a MEDLINE search to locate all published 
randomized controlled trials of psychotherapies identifi ed by 
their authors as being “psychodynamic” or “psychoanalytic.” 
We also used meta-analyses and review articles to identify trials 
(6, 8–11, 16–22), examined the reference lists of recovered articles, 
and consulted experts in the fi eld to ensure that we obtained a 
comprehensive list. All studies that randomized participants to 
two or more treatments, one of which was identifi ed as “psycho-
dynamic” or “psychoanalytic” treatment, were included. Stud-
ies that identifi ed themselves as precursors to larger and more 
complete studies were excluded even if randomization was per-
formed. To capture the full range of study quality, we did not use a 
sample size cutoff in selecting trials. Only studies with published 
articles in English were included. A total of 94 trials were identi-
fi ed that met inclusion and exclusion criteria.
Quality Measure: The RCT-PQRS
Items for the RCT-PQRS were generated by expert consensus. 
The experts included the subcommittee and several outside con-
sultants, all of whom were senior psychotherapy or pharmaco-
therapy researchers. Contributors included those with experience 
in performing studies of psychodynamic psychotherapy, CBT, 
pharmacotherapy, and combinations. Items were compared with 
those of the CONSORT standard as well as several other measures 
of quality of outcome trials to ensure that all major domains for 
assessing study adequacy were included (13, 14, 23–26).
The RCT-PQRS consists of 25 items (Figure 1) corresponding to 
elements of study design, execution, and reporting, each rated 0 
(poor description, execution, or justifi cation of a design elemen t), 
1 (brief description or either a good description or an appropri-
ate method/criteria but not both), or 2 (well described, executed, 
and, where necessary, justifi ed design element). Item 25, an 
“omnibus” item, was rated from 1 (exceptionally poor study) to 
7 (exceptionally good study). Because of the complex scientifi c 
choices involved in determining study design, the measure was 
designed to be administered by individuals experienced in read-
ing and conducting psychotherapy outcome trials.
Items were chosen so as to represent randomized controlled trial 
design and description elements that are crucial to the execution of 
a study that can be expected to yield reliable, valid, and reproduc-
ible data. No assumptions were made about whether individual 
design elements are already commonly implemented in such tri-
als. In fact, several items were specifi cally chosen with the knowl-
edge that they are not common practice (e.g., item 13, reporting of 
safety and adverse events) but with the conviction that they should 
agreement about what constitutes a well-conducted trial 
(13). The CONSORT (Consolidated Standards of Report-
ing Trials) Statement, which has been adopted by most 
major medical journals, identifi es 22 elements that are 
important in reporting randomized controlled trials (14). 
However, the CONSORT checklist and other similar mea-
sures, designed primarily to assess studies of pharmaco-
logical or medical interventions, fail to adequately assess 
the psychotherapy literature for several reasons. First, they 
do not include items that are specifi c and essential to psy-
chotherapy trials, such as the length of follow-up or the 
extent of training or supervision of psychotherapy. Sec-
ond, they focus on the quality of description in the writ-
ten article, with less explicit focus on what was done in the 
actual trial, thus deemphasizing such essential details as 
assessment of adherence to the treatment actually deliv-
ered. Third, they pay insuffi cient attention to the quality 
and credibility of comparison treatments, as this is less of 
an issue for studies using pill placebo for the comparison 
group. And fourth, psychometric evaluation of CONSORT 
items has never been reported, nor have the items been 
used to quantify overall quality scores. An extension of the 
CONSORT Statement to randomized trials of nonphar-
macological treatment (including, for example, surgery, 
technical interventions, devices, rehabilitation, psycho-
therapy, and behavioral intervention) published in 2008 
consists of further elaboration of 11 of the checklist items, 
addition of one item, and modifi cation of the fl ow diagram 
(15). Although helpful, this extension remains nonspecifi c 
to psychotherapy, focuses on description over conduct of 
the trials, and lacks psychometric evaluation.
As part of an effort to clarify the state of psychodynamic 
psychotherapy research, the Ad Hoc Subcommittee for 
Evaluation of the Evidence Base for Psychodynamic Psy-
chotherapy (appointed in 2004 by the APA Committee on 
Research on Psychiatric Treatments) developed the Ran-
domized Controlled Trial of Psychotherapy Quality Rat-
ing Scale (RCT-PQRS). This 25-item questionnaire was 
designed by experienced psychiatric and psychotherapy 
researchers from a variety of theoretical backgrounds as 
a systematic way to rate the quality of randomized con-
trolled trials of psychotherapy. The scale is designed to 
be used by individuals with considerable experience in 
reading and executing psychotherapy trials but requires 
only 10 to 15 minutes to rate, in addition to the time spent 
reading the paper to which it is applied. The scale yields a 
24-item total score that has good psychometric properties 
and captures the overall quality of design, implementa-
tion, and reporting of psychotherapy trials. (Item 25 is an 
omnibus item, more about which below.)
In this article, we report psychometric properties of 
the RCT-PQRS based on application of the scale to all 94 
randomized controlled trials of individual and group psy-
chodynamic psychotherapy published between 1974 and 
May 2010 that we were able to locate. We then describe 
the results of applying this measure to the psychodynamic 
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be a standard part of psychotherapy randomized controlled trial 
methodology. No a priori assumptions were made about the rela-
tive importance of different items for the overall quality of the trial.
We calculated a total score by computing the nonweighted sum 
of the fi rst 24 individual items. Although we investigated both the 
omnibus item and total scores, we believe that the fi rst 24 items 
are essential in guiding the thinking of the rater, and we did not 
intend to test the usefulness of a single item in the absence of a 
longer scale. The advantage of the total score is that it provides 
more variability and is explicitly based on 24 (relatively) inde-
pendent judgments, whereas the advantage of the omnibus item 
is that it allows the rater to give relative weight to strengths or 
weaknesses of the study that he or she feels are particularly rel-
evant (the sum arbitrarily weights all items equally). Therefore 
we intend to keep both metrics in our analyses. We estimated a 
priori that a total score of 24 would correspond to the minimum 
adequate total quality-of-study score, corresponding to an aver-
age value of 1 on each scale item. As this is the fi rst published use 
of the RCT-PQRS, no norms have yet been established. To illus-
trate the properties of the measure, we asked raters to score two 
well-known randomized controlled trials that are not included in 
this study (and do not include an explicitly psychodynamic treat-
ment group). The National Institute of Mental Health Treatment 
of Depression Collaborative Research Program, which compared 
CBT, interpersonal psychotherapy, and medication, received a 
total quality score of 40 and an item 25 score of 6 (27). The Treat-
ment for Adolescents With Depression Study, which studied the 
effect of fl uoxetine, CBT, and their combination in depressed ado-
lescents, received a total quality score of 38 and an item 25 score 
of 6 (28). Both of these are believed to represent a high standard of 
quality for a randomized controlled trial of psychotherapy.
Method of Rating
For each of the psychodynamic trials identifi ed, a single pub-
lished paper was selected that most thoroughly represented the 
methods and fi ndings of the study. Each study was then randomly 
assigned to one of fi ve senior raters (J.H.K., B.L.M., S.P.R., J.P.B., 
and M.E.T.). Each rater read the selected paper in its entirety and 
then completed the scale on the basis of the paper alone, dis-
regarding prior knowledge that he or she may have had about 
the study. Raters were encouraged to go back to the paper dur-
ing scoring to check on study details as needed. The reliability of 
these ratings has been described elsewhere (29). Interrater reli-
ability was assessed using the intraclass correlation coeffi cient 
(ICC) formula (ICC[1,1]) from Shrout and Fleiss (30) as imple-
mented by the INTRACC.SAS procedure (31) using the STAT soft-
ware package, version 9.1, of the SAS System for Windows (SAS 
Institute, Inc., Cary, N.C.). This formula is appropriate for a situ-
ation in which k (in this case, k=2) independent raters score each 
member of a sample but the identity of the raters changes at ran-
dom from one member of the sample to the next. The internal 
consistency of the fi rst 24 items was assessed using the standard 
formula for Cronbach’s alpha (32). For the fi rst 70 studies included 
in this review, the total score ICC was 0.76 and Cronbach’s alpha 
was 0.87. This indicates high interrater reliability of the total qual-
ity and high internal consistency of the items in the scale. For the 
purposes of this review, the rating of only a single senior rater was 
used for each study, as this is how the measure was designed to be 
used and is most likely how it will be used by other investigators.
The issue of whether raters were assessing the quality of the 
study itself or of the publication was an inevitable tension in data 
collection. Raters were instructed, for the sake of standardization 
and reliability, to base their ratings only on what was reported in 
the single article that was given to them. Whether a similar rule 
would be applied for future applications of this measure would 
depend on the resources and goals of the researchers. For this 
review, to collect and read all papers on a given study would have 
posed methodological challenges greater than those solved by 
FIGURE 1. Items in the Randomized Controlled Trial 
Psychotherapy Quality Rating Scalea
a Items 1–24 are rated 0 (poor description, execution, or justifi cation 
of a design element), 1 (brief description or either a good descrip-
tion or an appropriate method/criteria but not both), or 2 (well de-
scribed, executed, and, where necessary, justifi ed design element). 
Item 25 is rated from 1 (exceptionally poor study) to 7 (exception-
ally good study).
Description of subjects
 1. Diagnostic method and criteria for inclusion and exclusion 
 2. Documentation or demonstration of reliability of diagnostic 
methodology
 3. Description of relevant comorbidities
 4. Description of numbers of subjects screened, included, and 
excluded
Definition and delivery of treatment
 5. Treatment(s) (including control/comparison groups) are 
sufficiently described or referenced to allow for replication
 6. Method to demonstrate that treatment being studied is 
treatment being delivered (only satisfied by supervision if 
transcripts or tapes are explicitly reviewed)
 7. Therapist training and level of experience in the treatment(s) 
under investigation
 8. Therapist supervision while treatment is being provided
 9. Description of concurrent treatments (e.g., medication) 
allowed and administered during course of study (if patients on 
medication are included, a rating of 2 requires full reporting of 
what medications were used; if patients on medications are 
excluded, this alone is sufficient for a rating of 2)
Outcome measures
10. Validated outcome measure(s) (either established or newly 
standardized)
11. Primary outcome measure(s) specified in advance (though 
does not need to be stated explicitly for a rating of 2)
12. Outcome assessment by raters blinded to treatment group and 
with established reliability
13. Discussion of safety and adverse events during study 
treatment(s)
14. Assessment of long-term post-termination outcome (should 
not be penalized for failure to follow comparison group if this 
is a wait-list or non-treatment group that is subsequently 
referred for active treatment)
Data analysis
15. Intent-to-treat method for data analysis involving primary 
outcome measure
16. Description of dropouts and withdrawals
17. Appropriate statistical tests (e.g., use of Bonferroni correction, 
longitudinal data analysis, adjustment only for a priori 
identified confounders)
18. Adequate sample size
19. Appropriate consideration of therapist and site effects
Treatment assignment
20. A priori relevant hypotheses that justify comparison group(s)
21. Comparison group(s) from same population and time frame as 
experimental group
22. Randomized assignment to treatment groups
Overall quality of study
23. Balance of allegiance to types of treatment by practitioners
24. Conclusions of study justified by sample, measures, and data 
analysis, as presented (note: useful to look at conclusions as 
stated in study abstract)
25. Omnibus rating: Please provide an overall rating of the quality 
of the study taking into account the adequacy of description, 
the quality of study design, data analysis, and justification of 
conclusions
RANDOMIZED CONTROLLED TRIALS OF PSYCHODYNAMIC PSYCHOTHERAPY
22       ajp.psychiatryonline.org Am J Psychiatry 168:1, January 2011
using more than one paper per study (e.g., it would be hard to 
determine which publications were eligible and unfair to penal-
ize studies that had generated fewer overall publications). How-
ever, raters were instructed to base ratings of items not only on 
the quality and inclusivity of the publication (although this was 
inevitably a signifi cant part of what guided their ratings) but 
also on the quality of the study design captured in these items 
and the extent to which convincing justifi cation was provided for 
design decisions whose rationale might not be entirely clear to 
someone familiar with the fi eld of psychotherapy research. There-
fore, unlike the CONSORT standard, which is more instructive 
about a publication than about study design (although it clearly 
carries implications for the latter), the RCT-PQRS was intended 
to capture, as directly as possible, the quality of the study design.
Study Results and Comparator Type
We classifi ed the results of each study in terms of outcome at 
termination of treatment (psychodynamic psychotherapy com-
pared with any other group in which a statistical comparison 
was reported). We rated whether the psychodynamic group did 
better, did the same, or did worse than the comparison group at 
the end of treatment based on statistically signifi cant results from 
primary outcome measures specifi ed by the authors (see the data 
supplement that accompanies the online edition of this article). 
When differences between groups were not statistically signifi -
cant by the standards set by the study’s authors, the comparison 
was placed in the “no difference” group. If the primary outcome 
measures were either insuffi ciently specifi ed or provided hetero-
geneous results, we rated the outcome category on the basis of 
the authors’ summary of their fi ndings in the paper’s abstract. We 
discussed any ambiguity about these ratings until a consensus 
was reached. For every paper, we felt that a clear and uncontro-
versial categorization could be reached.
Each comparison group was classifi ed as “active” or “inactive,” 
following a distinction similar to that used by other authors (33). 
An active comparison group is one that received a specifi ed treat-
ment that has been validated by any previous empirical research 
for the disorder being treated or is considered a specifi c appro-
priate treatment by clinical consensus. This may include various 
forms of psychotherapy, as well as medication alone. For the pur-
poses of this review, the standard for an active treatment was set 
intentionally low in order to capture the distinction between these 
treatments and those that are clearly intended by the investigators 
to be nonspecifi c and/or easy targets to beat (the inactive treat-
ments). An inactive comparison group is any group that received 
no treatment at all (a no-treatment or waiting list control condi-
tion), treatment as usual, or a treatment that is not thought by any 
experts to be effective for the disorder being treated. Although Vin-
nars et al. (34) showed “treatment as usual” to be effi cacious for 
personality disorders, their research was conducted in Sweden, 
where strong, comprehensive universal health care with well-
articulated treatment descriptions for personality disorders is 
the national standard; therefore similar comparator groups were 
deemed “active.” However, most of the studies reviewed here were 
conducted in the United States, where “treatment as usual” often 
represents little or no treatment. Furthermore, because by its very 
nature, “treatment as usual” is nonstandardized, it most often 
belongs in the “inactive” category for these purposes. We discussed 
any ambiguous classifi cations until consensus was reached and 
all authors agreed that each classifi cation was ultimately uncon-
troversial according to the standards specifi ed above.
Results
Study Characteristics
The 94 studies included in this analysis were from arti-
cles published in English between 1974 and May 2010. 
Total study sample size (combining patients from all 
treatment groups in a given randomized controlled trial) 
ranged from 10 to 487 (median=73). Seventy-two studies 
evaluated the effects of individual psychodynamic psy-
chotherapy lasting less than 1 year, 12 studies looked at 
individual psychodynamic psychotherapy lasting 1 year 
or longer, and 17 studies were of psychodynamic group 
psychotherapy. There are no existing randomized con-
trolled trials of psychoanalysis as currently defi ned by the 
American Psychoanalytic Association (minimal session 
frequency four times per week).
The number of comparison groups (excluding the group 
treated with psychodynamic psychotherapy) ranged from 
one to three (mean=1.4, SD=0.71). The frequencies of vari-
ous types of comparison groups are presented in Table 1. 
The most common comparison group was CBT (18 stud-
ies, 19%), followed by supportive therapy (11 studies, 12%). 
Contained within the 94 studies were 103 direct compari-
sons between psychodynamic psychotherapy and a non-
dynamic alternative treatment. Eleven studies did not 
report such a comparison (eight reported comparisons 
between two or more types of psychodynamic psychother-
apy, and three failed to report comparisons of outcome at 
termination). Fourteen studies reported the results of sep-
arate comparisons between psychodynamic psychother-
apy and two other treatments, and three studies reported 
comparisons with three other treatments. Of the 103 direct 
comparisons, 63 (61%) compared psychodynamic psycho-
therapy with an active treatment, and 40 (39%) compared 
psychodynamic psychotherapy with an inactive treatment.
The major diagnostic categories treated in the 94 studies 
are summarized in Table 2. The most common diagnostic 
categories were depressive disorders (27%), personality 
disorders (14%), medical illness (11%), eating disorders 
(11%), anxiety disorders (10%), and substance abuse (7%). 
Because a wide range of methods were used for assessing 
the diagnostic category of the patients in these studies, sub-
dividing the results of the review by diagnosis would result 
in combining across heterogeneous categories; meaningful 
results cannot be reported in terms of diagnostic categories.
TABLE 1. Comparison Group Categories in 94 Randomized 
Controlled Trials of Psychodynamic Psychotherapya




Family therapy  7
Group therapy 11
Medication only  6
Waiting list 13
Treatment as usual 13
No treatment  8
Miscellaneous (e.g., yoga, dietary advice, 
primary care, relaxation, recreation)
18
a Because some studies had more than one comparison group, a 
study may be counted in more than one category.
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psychodynamic psychotherapy and an inactive compara-
tor. Thirty-nine (62%) of the 63 comparisons of psychody-
namic psychotherapy and an active comparator came from 
studies with a mean total quality of at least 24. Twenty-four 
(60%) of the 40 comparisons of psychodynamic psycho-
therapy and an inactive comparator came from studies 
with a mean total quality of at least 24.
Of the 63 comparisons between psychodynamic psy-
chotherapy and an active comparator, six (10%) showed 
greater improvement in the psychodynamic group, 10 
(16%) showed greater improvement in the comparator 
group, and the remainder (47 studies, 75%) showed no 
signifi cant difference between the groups. Of the 40 com-
parisons between psychodynamic psychotherapy and an 
inactive comparator, 27 (68%) showed greater improve-
ment in the psychodynamic group, one (3%) showed 
greater improvement in the comparator group, and 12 
(30%) showed no signifi cant difference between groups.
Associations Between Study Outcome and Quality
Mean total quality and item 25 scores were calculated 
separately for studies with active and inactive comparators 
that found signifi cant or no differences between groups 
at termination (Table 3). No relationships were observed 
between quality of study and the nature of the compara-
tor (active or inactive), between quality of study and the 
outcome of the comparison (dynamic therapy superior or 
inferior, or no difference), or between quality of study and 
an interaction of comparator type and outcome.
Sixty-three of the 103 comparisons described above 
had a total quality score of 24 or above (the cutoff for a 
Quality Scores
The methods used to standardize the RCT-PQRS 
and some initial results based on 69 of the randomized 
 controlled trials reviewed here have been described else-
where (29). An updated version of these fi ndings is sum-
marized below. The overall quality score of the 94 studies 
was normally distributed, with a mean of 25.1 (SD=8.8; Fig-
ure 2). More recently conducted studies had higher aver-
age total quality scores (29). The omnibus item score (item 
25) showed the same trend over time (29). Individual item 
scores, although limited in their potential for interpreta-
tion because of the absence of high single-item interrater 
reliability, suggest the relative strengths and weaknesses 
of various study characteristics. For four of the 24 items, at 
least half of the studies were scored as “good” (i.e., a rating 
of 2): item 4 (description of numbers screened, included, 
and excluded), item 5 (treatment suffi ciently described 
or referenced), item 20 (comparison groups justifi ed by a 
priori hypotheses), and item 21 (comparison groups from 
same population and time frame). For three items, at least 
half of the studies were scored as “poor” (i.e., a rating of 0): 
item 13 (reporting of safety and adverse events), item 15 
(intent-to-treat method reported in data analysis), and item 
19 (consideration of therapist and study site effects). For 23 
of 24 items, the mean item score was stable or increased 
across the time periods into which the studies were divided 
(1974–1988, 1989–1997, 1998–2004, 2005–2010). The mean 
score of item 14 (long-term post-termination outcome 
assessment) increased between the fi rst two periods but 
then dropped and was lowest in the past 5 years, possi-
bly refl ecting greater diffi culty in funding acquisition and 
acknowledgment of the inherent diffi culties in interpreting 
outcome data because of artifacts of intervening nonstudy 
interventions that increase over time.
Rater Effects
The mean total quality scores of the fi ve senior raters 
were 20.4, 24.1, 25.0, 25.4, and 27.0. For the three raters 
with psychodynamic orientations, the mean overall qual-
ity rating was 23.6 (SD=2.8), and for the two raters with 
a nondynamic orientation, the mean rating was 25.6 
(SD=2.1). There was no signifi cant relationship between 
mean quality rating and theoretical orientation.
Study Outcome
In the sample of 94 outcome studies, we found a total 
of 103 comparisons between a psychodynamic treatment 
and a set of either inactive or active comparators. In stud-
ies with more than one active or more than one inactive 
comparator, we treated the comparisons within each set 
together because the fi ndings within a set of active or inac-
tive almost always matched and because we did not want to 
improperly weight studies with more comparison groups in 
our analyses, as these studies tended to have smaller num-
bers of patients per group and were underpowered. Of the 
103 comparisons, 63 were between psychodynamic psy-
chotherapy and an active comparator and 40 were between 
TABLE 2. Diagnostic Categories of Patients in 94 Random-
ized Controlled Trials of Psychodynamic Psychotherapy
Diagnostic Category Number of Studies
Depression (major depression, geriatric 
depression, postpartum depression, grief, 
minor/subsyndromal depression)
25
Personality disorders (borderline personality 
disorder, cluster C symptoms, avoidant 
symptoms, high utilizers of psychiatric 
services)
13
Complicated medical illnesses (chronic pain, 
irritable bowel syndrome, chronic peptic 
ulcer, Crohn’s disease, chronic obstructive 
pulmonary disease, rheumatic disease, 
atopic dermatitis)
10
Eating disorders (anorexia, bulimia, obesity, 
binge eating disorder)
10
Anxiety disorders (panic disorder, 
posttraumatic stress disorder, social anxiety, 
generalized anxiety)
 9
Substance abuse (opiates, cocaine, alcohol)  7




Miscellaneous (childhood sexual abuse, mixed 
disorders)
14
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inferior to a comparator. Twenty-four of the 63 higher-
quality comparisons looked at dynamic treatment against 
an “inactive” comparator, and 18 of these found dynamic 
treatment to be superior. When the total quality and item 
25 scores of the higher-quality subgroup (63 studies) were 
analyzed with respect to outcome, no signifi cant differ-
ences were found between groups (Table 4).
Discussion
In this evaluation, we examined a large amount of study-
derived data collected to describe the utility of psychody-
namic psychotherapy for psychiatric illness. On this basis, 
it appears that there is both good and bad news about the 
quality of randomized controlled trials of psychodynamic 
psychotherapy. The good news is that there are at least 94 
randomized controlled trials published to date addressing 
the effi cacy of psychodynamic psychotherapy, spanning a 
range of diagnoses, and more than half of these (57%) are 
“reasonably well done” study established from the face 
validity of the measure). Because some studies contain 
more than one comparison, these 63 comparisons repre-
sent 50 of the original 94 studies. Four additional studies 
that were excluded from the list of comparisons (because 
they only compared psychodynamic therapies to each 
other or because they did not report outcome at termina-
tion) also had total quality scores of 24 or higher. There-
fore, a total of 54 of the original 94 studies reviewed were 
deemed “reasonably well done” by this measure.
Thirty-nine of the 63 comparisons with adequate qual-
ity compared a dynamic treatment and an active com-
parator: six showed dynamic treatment to be superior, fi ve 
showed dynamic treatment to be inferior, and 28 showed 
no difference. Notably, 19 of the 24 active comparisons 
that were eliminated from this analysis because of a total 
quality below 24 came from the group that showed no dif-
ference between two treatments and the remaining fi ve 
came from the group that showed dynamic therapy to be 
TABLE 3. Mean Total Quality Scores and Item 25 Scores, by Outcome Classifi cation, for All Comparisons (103 Comparisons)
Comparator
Psychodynamic Treatment > 
Comparator
Psychodynamic Treatment = 
Comparator
Psychodynamic Treatment < 
Comparator
Total Quality Score Item 25 Score Total Quality Score Item 25 Score Total Quality Score Item 25 Score
Mean SD N Mean SD Mean SD N Mean SD Mean SD N Mean SD
Active comparator 
(63 comparisons)
30.1 6.7  6 4.7 1.2 25.7  8.7 47 4.2 1.6 25.9 10.6 10 4.4 1.8
Inactive comparator 
(40 comparisons)
26.8 8.7 27 4.5 1.4 24.4 10.1 12 4.0 1.4 16 —  1 2 —
TABLE 4. Mean Total Quality Scores and Item 25 Scores, by Outcome Classifi cation, for Studies With Total Quality Scores ≥ 
24 (63 Comparisons)
Comparator
Psychodynamic Treatment > 
Comparator
Psychodynamic Treatment = 
Comparator
Psychodynamic Treatment < 
Comparator
Total Quality Score Item 25 Score Total Quality Score Item 25 Score Total Quality Score Item 25 Score
Mean SD N Mean SD Mean SD N Mean SD Mean SD N Mean SD
Active comparator 
(39 comparisons)
30.1 6.7  6 4.7 1.2 31.2 5.8 28 5.1 1.1 34.2 7.9 5 5.8 1.1
Inactive comparator 
(24 comparisons)




























FIGURE 2. Histogram of 24-Item Total Quality Scores for 94 Randomized Controlled Trials of Psychodynamic Psychotherapy
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Therefore, it is our conclusion that although the overall 
results are promising, further high-quality and adequately 
powered randomized controlled trials of psychodynamic 
psychotherapy are urgently needed. The standards by 
which a treatment is considered “evidence-based” for the 
purposes of inclusion in practice standards, educational 
curricula, or health care reimbursement vary widely. Per-
haps the most commonly cited standard, fi rst published by 
Chambless and Hollon in 1996 from an American Psycho-
logical Association Division 12 (clinical psychology) task 
force (37), requires at least two well-conducted trials using 
manuals, showing superiority or equivalence for a specifi c 
disorder, and performed by separate research groups, for 
a treatment to be considered “well-established.” By this 
standard, the 25 high-quality trials reviewed could have 
been more than enough for psychodynamic psycho-
therapy to be considered “empirically validated.” How-
ever, these 25 trials covered a wide range of diagnoses 
and used different manuals or forms of dynamic therapy. 
In addition, the signifi cant number of trials that failed to 
fi nd differences between dynamic and active or inactive 
comparators, most of which were not powered for equiv-
alence, as well as a handful of trials that found dynamic 
therapies to be inferior to active comparators, suggest that 
more work is needed. It remains necessary to identify spe-
cifi c dynamic treatments that are empirically validated for 
specifi c disorders.
One fi nding of this review is that the clearest predictor 
of outcome from randomized trials of psychodynamic 
psychotherapy is whether or not the treatment was tested 
against an active or an inactive comparison treatment. We 
suspect that this fi nding is common to randomized con-
trolled trials of all psychotherapies. There is no apparent 
relationship in this group of studies between study quality 
and the outcome measured in that study.
We have taken a highly critical view of data collected in 
support of psychodynamic psychotherapy in this evalu-
ation. Few domains of psychiatric intervention have yet 
been evaluated so critically, and we emphasize that many 
domains of psychotherapy outcome research (i.e., CBT, 
cognitive-behavioral analysis system of psychotherapy, 
interpersonal psychotherapy, and supportive psycho-
therapy, to name some) may not fare signifi cantly better, 
despite the far greater number of outcome studies within 
these other domains to evaluate. We are currently embark-
ing on a similar review of studies of CBT for depression. 
We believe that this is an appropriate stance, and we antic-
ipate that this assessment can help move psychotherapy 
research in a direction toward better-designed outcome 
studies in the future. Thus far, proponents of other studied 
forms of specifi c psychotherapy, most notably CBT, have 
yet to dissect the quality of studies that support its effi cacy.
For three items in the RCT-PQRS, at least half of the 
studies were scored as “poor”: item 13 (reporting of safety 
and adverse events), item 15 (intent-to-treat method 
reported in data analysis), and item 19 (consideration of 
of adequate quality. The 94 studies represent 103 compari-
sons between the outcome of psychodynamic psychother-
apy and a nondynamic comparator at termination. In the 
63 comparisons of dynamic treatment and an active com-
parator, dynamic treatment was found to be superior in 
almost 10% and inferior in 16%, and the analyses failed to 
fi nd a difference in almost 75%. In the 40 comparisons of 
dynamic treatment and an inactive comparator, dynamic 
treatment was superior in 68%, there was no evidence for 
difference in 30%, and dynamic treatment was inferior in 
one study. We obtained similar results if only studies of 
good quality are included. In comparisons of good qual-
ity studies involving dynamic treatment against an active 
comparator, dynamic treatment was superior in 15% and 
inferior in 13%, and evidence was lacking in either direc-
tion in 72%. In comparisons against an inactive treatment, 
dynamic treatment was superior in 75% and lacked evi-
dence in either direction in 25%.
However, it is clear that there are signifi cant quality 
problems in a signifi cant percentage of randomized con-
trolled trials of psychodynamic psychotherapy, and this 
may be true for trials of other psychotherapies as well. 
Based on the 94 studies reviewed here, reporting of safety 
and adverse events, intent-to-treat method in data analy-
sis, and consideration of therapist and study site effects 
are lacking. Furthermore, 57% of all comparison and 54% 
of comparisons from studies of adequate quality failed 
to fi nd any statistical differences between outcome from 
psychodynamic treatment and a comparator. As Milrod 
(35) has pointed out, if a randomized controlled trial is not 
powered for equivalence (that is, lacks suffi cient enough 
power to detect differences between groups such that the 
absence of a signifi cant difference can be interpreted as 
equivalence in effi cacy or effectiveness of the treatments), 
it is impossible to conclude from the absence of a fi nding 
that dynamic treatment is as good as or not worse than the 
comparator treatment. In fact, if we use the rough approx-
imation that a total sample size of at least 250 is required 
in order to be powered for equivalence (the actual number 
depends on the measures used), one of the comparisons 
reviewed here that failed to show a difference between 
psychodynamic treatment and an active comparator met 
that criterion (36).
When considered from this perspective, an important 
fi nding is that of 63 statistical comparisons based on ran-
domized controlled trials of adequate quality, six showed 
psychodynamic psychotherapy to be superior to an active 
comparator, 18 showed it to be superior to an inactive 
comparator, and one showed it to be equivalent to an 
active comparator. The empirical support for psychody-
namic psychotherapy comes down to these 25 compari-
sons (in boldface in online data supplement). Most of the 
rest of even the trials of adequate quality are uninforma-
tive (33 studies), and several suggest that psychodynamic 
psychotherapy is worse than an active or inactive compar-
ator (fi ve studies).
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RCT-PQRS that would allow for greater single-item reli-
ability across raters. Lack of reliability limits our ability to 
interpret individual item scores. Although a manual would 
likely improve item reliability, it would increase the time 
it takes to learn and apply the measure and might not 
affect the overall scores. Third, we have not yet collected 
suffi cient data from the RCT-PQRS to study other ways of 
aggregating or weighting individual items. We anticipate 
performing the appropriate analyses as we collect data on 
a larger number and broader range of randomized con-
trolled trials of psychotherapies. Finally, given that raters 
of the studies are not blind to study outcome or, in most 
cases, the allegiance of the study authors, the quality scale 
is theoretically susceptible to bias. Blinding the studies by 
removing the names of treatments or the direction of fi nd-
ings would be diffi cult if not impossible, and the blinding 
process itself would be subject to biases. We addressed the 
potential for bias by making sure that our raters (and the 
designers of the scale) were drawn from a range of areas 
of clinical and research expertise, including pharmaco-
therapy, CBT, and psychodynamic psychotherapies. We 
observed no signifi cant relationship between quality rat-
ings and theoretical orientation of raters. In fact, the mean 
total quality score was slightly lower for raters with a psy-
chodynamic orientation than for those without.
We hope that this better-operationalized evaluation of 
the quality of psychotherapy outcome studies will help 
guide investigators across all areas of psychotherapy 
research toward more scientifi cally credible, better-artic-
ulated research.
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therapist and study site effects). Individual item scores 
must be regarded with caution because we have not yet 
established a high degree of interrater reliability on indi-
vidual items. However, we believe that all three of these 
items represent signifi cant defi cits in the psychodynamic 
psychotherapy research literature that are still being 
insuffi ciently addressed (1). It is well known by clinicians 
that all effi cacious treatments, whether they be psycho-
therapy or psychopharmacology, carry with them some 
risk of adverse effects, yet the randomized controlled trial 
literature in psychotherapy in general does not systemati-
cally report and discuss adverse events as do, for example, 
most good studies of medication (2). While there has been 
signifi cant improvement in the area of intent-to-treat 
analysis, many randomized controlled trials of psychody-
namic psychotherapy still focus primarily on “completer” 
analyses and do not adequately employ the intent-to-
treat method, which is a standard of the evidence-based 
medicine literature. Although intent-to-treat analyses also 
have certain limitations, they are the best starting point 
for addressing patient dropout in considering which treat-
ments work best (38–40). Finally, a large literature sup-
ports the importance of individual therapist and study 
site effects in psychotherapy outcome (41–43), but the 
psychotherapy randomized controlled trial literature has 
not yet adequately responded by incorporating such con-
siderations into a discussion of results, and even less into 
study design.
The RCT-PQRS focuses only on the reporting, execu-
tion, and justifi cation of design decisions made in a 
given report of a randomized controlled trial, but not on 
how these decisions affect the broader question of when 
results can be applied to real-world clinical practice. In 
other words, the measure addresses the importance of 
accurately and reliably quantifying the internal validity 
of a randomized controlled trial, while tracking generaliz-
ability less (3). As one example of this, the diagnostic cat-
egories described in Table 2 are just one conventional way 
of parsing the patient samples and are by no means the 
only way to subdivide these studies. None of the analyses 
in this article relied on diagnostic categories. However, 
future quality-based reviews and meta-analyses will need 
to address this issue.
The development and application of our quality mea-
sure have several signifi cant limitations. First, the accu-
racy of our ratings is necessarily limited by the extent of 
the information provided by the authors in their study 
descriptions. In some cases, the extent to which the 
authors describe a comparison treatment such as “treat-
ment as usual” as active or inactive could have important 
consequences in rating the study. However, in our rat-
ing of active versus inactive comparator treatments, we 
observed no signifi cant differences between raters and 
therefore do not believe that there was much ambigu-
ity in these ratings for the articles reviewed. Second, we 
have not yet developed and published a manual for the 
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